General Information
We are a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies, or mAbs, in the disease areas of immunology and oncology. A mAb is a type of protein that is produced by a single clone of cells or cell line and made to bind to a specific substance in the body.
Employees: 89
Founded: 2010
Contact Information
Address 7 Clarke Drive, Cranbury, NJ 08512, US
Phone Number (609) 619-3990
Web Address http://www.oncobiologics.com
View Prospectus: Oncobiologics
Financial Information
Market Cap $136.8mil
Revenues $3.3 mil (last 12 months)
Net Income $-63.6 mil (last 12 months)
IPO Profile
Symbol ONSIU
Exchange NASDAQ
Shares (millions): 5.8
Price range $6.00 - $6.00
Est. $ Volume $35.0 mil
Manager / Joint Managers Jefferies/ Barclays
CO-Managers Cantor Fitzgerald & Co.
Expected To Trade: 5/13/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change